Your browser does not support iframes.
The CNS runs our lives. Diseases of the CNS ruin lives. These are diseases that are at the forefront of our thinking. There is still much we do not know about the biological mechanisms behind disorders of the brain and the CNS. However, progress is being made, and our understanding is growing day by day. We are working tirelessly to turn this knowledge into insights and to turn these insights into treatments.We are developing a focused pipeline of new drugs and novel treatments to meet patient and societal needs in a range of CNS conditions. We are constantly looking for new targets and approaches to treat diseases like multiple sclerosis (MS), Neurodegenerative diseases, pain and migraine.
We are facing a huge rise in the prevalence of neurodegenerative diseases. Devastating conditions such as MS, Alzheimer’s disease, Parkinson’s Disease (PD) and Huntington Disease (HD) are expected to rise by between 30-50% by 2030.Neurodegenerative diseases affect people of all ages, and are on the increase across all age groups. However one contributing factor stands out: our aging society.The number of people over the age of 60 in the world is expected to triple to 22% of the population in 2050 compared to 8% in 1950.
Physically, financially and emotionally destructive to both patients and their families, neurodegenerative diseases represent a huge burden. In the US alone, the direct costs of Alzheimer’s disease are estimated to be 200B annually, and across the world, 1% of global GDP is consumed by the impact of dementia.
We are moving in the right direction – slowly. Our understanding of underlying biology and physiology have improved significantly. In addition, advances in science and technology have provided us with the ability to diagnose patients much earlier in their disease progression. That informs research directions and is enabling the emergence of new treatment paradigms that could potentially change the course of disease.An example of this is our understanding that there are similar mechanisms at work and convergent pathways in the pathogenesis of Alzheimer’s, HD, MS and PD. This gives us targets to aim for.
Teva is a major player in the treatment of CNS disorders. We have developed and market world-leading treatments in MS, PD, and sleep disorders. We also have an exciting set of programs aimed at answering some key questions in the treatment of pain, migraine, and multiple neurodegenerative diseases. Our work in this area builds upon the inherent strength of Teva’s unique makeup. We are integrating the best of our discovery research, our innate knowledge from our generic and specialty portfolios (including both small molecules and biologics), our delivery system abilities and other advanced technologies. This creates a broad and varied pipeline that aims to address key unmet patient and societal needs.
We are working on enhancing the current standard of care in MS, as well as new approaches. In particular, a neuroprotective strategy aimed at slowing the progression of the disease.We also have a promising two pronged program that could provide breakthroughs in the treatment of HD.To address the need for effective treatments of pain, we have an exciting platform focused on the major issue of opioid abuse. This abuse severely impacts the effective management of pain.In addition, we are developing a novel Nav1.7 inhibitor, a new target for the treatment of osteoarthritic and neuropathic pain.We are also building a franchise in migraine that aims to provide best-in-class management of both the acute and chronic aspects of this devastating condition.